MedTrace Logo

A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repeated Doses In Healthy Adult Subjects

NCT00504439 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2017-08-03

No results posted yet for this study

Summary

To assess safety of SB-656933 following repeat dosing for 14 days.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

SB-656933-AAA

The doses of SB-656933 (20 mg, 50 mg or 100 mg) will be provided as a combination of 10 mg and 50 mg tablets of SB-656933-AAA. The tablets will be administered orally.

DRUG

Matching placebo

SB-656933-AAA matching placebo tablets will be administered orally.

DRUG

Simvastatin

Simvastatin will be provided as a 40 mg tablet.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-06-04
Primary Completion
2007-09-06
Completion
2007-09-06

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00504439 on ClinicalTrials.gov